Abstract
Objectives: People with cystic fibrosis (CF) are at risk of fat-soluble vitamin deficiency due to pancreatic insufficiency. Routine supplementation and monitoring of fat-soluble vitamin levels are undertaken. Studies show ivacaftor improves pancreatic function, and it is expected that elexacaftor/tezacaftor/ivacaftor (ETI) has similar effects. This study aimed to assess changes in fat-soluble vitamin levels in children starting ETI therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
